<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytokeratin 7 (CK7) and 20 (CK20) are used for the differential diagnosis of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), which are usually CK7-/CK20+, and other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In our study, we performed immunohistochemical staining with CK7 and CK20 in 52 randomly selected cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and analyzed microsatellite instability status and BRAF mutations to identify those factors that may determine the changing pattern of CK7/CK20 immunophenotype in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>CK7 was negative in <z:hpo ids='HP_0000001'>all</z:hpo> microsatellite stable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>), but <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0002038'>carcinomas</z:mp> presenting microsatellite instability (MSI) and BRAF mutations were diffusely positive for this marker </plain></SENT>
<SENT sid="3" pm="."><plain>CK20 was diffusely expressed in 79.06% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Regarding MSI, in case with no BRAF mutations, a progressive decrease in CK20 expression was noted, and in BRAF-mutated <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, no expression of CK20 was observed </plain></SENT>
<SENT sid="5" pm="."><plain>It seems that in case of MSI located on the proximal colon, which also presents BRAF mutations, CK20/CK7 may present a changing immunophenotype pattern, which may complicate the differential diagnosis of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This is the first reported study of the relationship between CK20/CK7 immunophenotype, BRAF mutations and microsatellite status in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>